The changing prognosis of melanoma

被引：14

作者：

Buzaid A.C. ^{[1
]}

Anderson C.M. ^{[2
]}

机构：

[1] Oncology Center, Hospital Sirio-Libanês, 01308-050, São Paulo, SP

[2] Department of Medicine, Hematology/Oncology, Ellis Fischel Cancer Center, University of Missouri Health Sciences Center, 65203, Columbia, MO

来源：

Current Oncology Reports | 2000年 / 2卷 / 4期

关键词：

Melanoma; Clin Oncol; Sentinel Node Biopsy; Cutaneous Melanoma; Wide Local Excision;

D O I：

10.1007/s11912-000-0025-9

中图分类号：

学科分类号：

摘要：

Cutaneous melanoma is a significant and increasing clinical problem. Knowing accurately the prognosis in a given patient is critical for treatment decisions and for optimal patient education. In this article we discuss the most current information regarding prognostic factors in early-stage and advanced malignant melanoma. Tumor thickness and ulceration are the most important predictors for primary melanoma. Number of positive lymph nodes is the most powerful predictor for stage III patients, and sites of disease and lactase dehydrogenase levels are the most useful predictors in metastatic disease.

引用

页码：322 / 328

页数：6

共 31 条

[21]

Calabro A, Singletary S, Balch C, Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases, Arch Surg, 124, pp. 1051-1055, (1989)

[22]

Singletary S, Tucker S, Boddie A, Multivariate analysis of prognostic factors in regional cutaneous metastases of extremity melanoma, Cancer, 61, pp. 1437-1440, (1988)

[23]

Brown C, Zitelli J, The prognosis and treatment of true local cutaneous recurrent malignant melanoma, Dermatol Surg, 21, pp. 285-290, (1995)

[24]

Cavaliere R, Cavaliere F, Deraco M, Hyperthermic antiblastic perfusion in the treatment of stage IIIA-IIIAB melanoma patients: comparison of two experiences, Melanoma Res, 4, pp. 5-11, (1994)

[25]

Sutherland C, Mather F, Krementz E, Factors influencing the survival of patients with regional melanoma of the extremity treated by perfusion, Surg Gynecol Obstet, 164, pp. 111-118, (1987)

[26]

Barth A, Wanek L, Morton D, Prognostic factors in 1,521 melanoma patients with distant metastases, J Am Coll Surg, 181, pp. 193-201, (1995)

[27]

Sirott M, Bajorin D, Wong G, Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis, Cancer, 72, pp. 3091-3098, (1993)

[28]

Deichmann M, Benner A, Bock M, S100-b, melanomainhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer Stage IV melanoma, J Clin Oncol, 17, pp. 1891-1896, (1999)

[29]

Franzke A, Probst-Kepper M, Buer J, Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma, Br J Cancer, 79, pp. 40-45, (1998)

[30]

Keilholz U, Conradt C, Legha S, Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients, J Clin Oncol, 16, pp. 2921-2929, (1998)

← 1 2 3 4 →